Author: Admin
New Diagnostic Test for Neurofilament
Biomarkers are measures reflective of biological processes that occur in the body. In the setting of disease, biomarkers may be used for diagnostic, prognostic or treatment monitoring purposes.
Challenge Me to Find the Path to a Faster Diagnosis of ALS

With funds raised through the ALS Ice Bucket Challenge, The ALS Association has been able to invest significantly in the identification of biological indicators (or biomarkers) for ALS.
Experimental Drug Shows Promise for Genetic Form of ALS (Links to an external site)
An early stage trial of an investigational therapy for amyotrophic lateral sclerosis (ALS) suggests that people could tolerate the experimental drug and, in exploratory results, the experimental drug was linked to possible slower progression in people with a genetic form of the disease caused by mutations in a gene called superoxide dismutase 1 (SOD1).
Experimental treatment could be ‘game-changing’ for genetic ALS, experts say (Links to an external site)
(CNN) An experimental treatment for the rapidly progressive disease ALS, or amyotrophic lateral sclerosis, has been called potentially “game-changing.”
Scientists Reverse Alzheimer’s-Like Symptoms in Mice (Links to an external site)

Engadget states, “Scientists have discovered a way of counteracting proteins that cause Alzheimer’s-like symptoms including memory loss. Researchers at Washington University in St. Louis, Missouri focus on tau protein tangles.” in an article about Dr. Miller’s 2017 STM publication.
Scientists Stop and Reverse Alzheimer’s-Related Brain Damage in Mice (Links to an external site)
A news release by MNT examines Dr. Miller’s 2017 STM publication. “The team studied the effects of the synthetic molecules on crab-eating macaques. They administered two doses of antisense oligonucleotides or two doses of a placebo, 1 week apart, directly into the cerebrospinal fluid – as one would when treating humans. The trial revealed that, in monkeys […]
Molecule Throws Roadblock in Alzheimer’s Path (Links to an external site)

An article by New Atlas describing Dr. Miller’s STM work states, “When it comes to the drama of Alzheimer’s disease, the compound in the starring role as the villain is tau. It’s a protein that normally helps our neurons function properly, but one that can clump together into plaques that damage brain cells. Now researchers have […]
New DNA-Like Drugs Show Promise in Treating Alzheimer’s (Links to an external site)

An article by Scientific American describes Dr. Miller’s Science Translational Medicine publication. “The small molecules cleared and prevented tau buildup in mice and monkeys.”
Antisense Oligos Tango with Tau Transcripts to Reverse Tauopathy (Links to an external site)

In an article about Dr. Miller’s newest Science Translational Medicine publication, ALZFORUM writes, “In collaboration with the pharmaceutical company Ionis in Carlsbad, California, Timothy Miller and his colleagues at Washington University in St. Louis designed a potent ASO that shuts down human tau gene expression in transgenic mouse models.”
Publication by Mariah L. Hoye, PhD Candidate
Congratulations to Miller Lab member Mariah L. Hoye on her publication! Mariah is a PhD candidate who is studying microRNAs, which are small compounds that regulate a variety of processes in the body, and their role in ALS disease progression. Her manuscript that investigates microRNAs specific to motor neurons in ALS rodent models was recently […]
Video: C9 ID: Accelerating a therapy for ALS patients with C9 mutations

In this video Dr. Timothy Miller provides an excellent explanation of how ALS works in the body and what researchers are doing to bring a therapy to ALS patients, especially those with mutation in the C9ORF72 gene.
Publication by Kathleen Schoch, PhD
Congratulations to Miller Lab member Kathleen Schoch on her publication! Dr. Kathleen Schoch is a postdoctoral research assistant in the Miller Lab who focuses on dementias characterized by the pathological accumulation of the protein “tau”. She published a paper in Neuron that examined the potential of a unique tau-lowering therapeutic strategy to treat Alzheimer’s disease, […]
Video: Advances in ALS Treatment

Washington University neurologist Timothy Miller, MD, discusses advances in ALS treatment.
Dr. Timothy Miller Wins Sheila Essey Award for ALS Research (Links to an external site)
The ALS Association, in partnership with the AAN and the American Brain Foundation, are awarding research funding to Timothy M. Miller, M.D., Ph.D., the David Clayson Professor of Neurology from the Washington University School of Medicine in St. Louis. The award recognizes significant research contributions in the search for the causes, prevention, and cure for amyotrophic lateral sclerosis (ALS). Since 1996, The ALS Association and the American Academy of Neurology have jointly chosen recipients of the award.
Ste. Genevieve Riverdogs Baseball Team Supports ALS Research

Prior to the final game of the season, the Ste. Genevieve Riverdogs baseball team surprised Coach Jeremy Hoog with a touching tribute as well as a donation to Dr. Timothy Miller’s ALS Research Lab in honor of Coach Hoog’s mother – and the Riverdogs’ biggest fan – Cheryl.
Medical Research Roundup: Dr. Tim Miller Awarded Research Grant from NIH (Links to an external site)
The Miller Lab has found differences between healthy people and people with amyotrophic lateral sclerosis (ALS) in biomolecules known as microRNAs. This project seeks to understand the microRNA differences and the effect of adjusting them to try to develop new diagnostic tests or treatments for ALS.
Dr. Timothy Miller and Team Win the TDP-43 Biomarker Grand Challenge (Links to an external site)
The team is developing a unique imaging biomarker to track TDP-43, a protein found in almost all cases of ALS.
ALS Ice Bucket Challenge helps fund Washington University’s research

Dr. Timothy Miller is featured in this news release describing how the money raised in the ALS Ice Bucket Challenge has helped discover new genetic causes of this disease. KSDK TV St. Louis
NEALS Webinar: “C9: From ID (Identification) to Therapy”

Dr. Timothy Miller, Washington University, and Dr. Merit Cudkowicz, Massachusetts General Hospital, provide an update on the C9orf72 Natural History Study and discuss therapies in development for C9 patients.
Phase 1 Clinical Trial to Test BIIB067 in People with ALS Currently Recruiting Participants
MDA announces enrollment in the Phase I/II trial of SOD1 antisense oligonucleotides. Dr. Timothy Miller led the first trial of these SOD1 ASOs in ALS patients and is now the academic Principle Investigator for the Phase I/II trial, sponsored by Biogen Idec and Ionis Pharmaceuticals.
Genetic Mutations Linked to Higher Proportion of ALS Cases Than Previously Believed (Links to an external site)
New research indicating genetic mutations may underlie more ALS cases than scientists originally thought. Dr. Miller’s close colleague Dr. Matthew Harms states, “To our surprise, we found that 26 percent of sporadic ALS patients had potential mutations in one of the known ALS genes we analyzed. This suggests that mutations may be contributing to significantly more ALS cases.”
ALS Trial Shows Novel Therapy is Safe (Links to an external site)
Highlights the exciting new results from Dr. Miller’s first Phase I trial of SOD1-targeting ASOs, stating that the investigational treatment for inherited forms of ALS has passed an early clinical trial for safety.
Breakthrough ALS Research at Washington University (Links to an external site)
Dr. Miller featured in news article and video about his Phase I clinical trial of antisense oligonucleotides targeting the SOD1 protein in ALS patients with SOD1 mutations.
Video: 2011 MDA Telethon ALS Research Update

MDA presents an update regarding research on ALS, featuring Dr. Timothy M. Miller from Washington University in St. Louis. MDA is supporting a clinical trial of antisense therapy seeking to counteract the affects of a toxic version of the protein SOD1 in patients with an inherited form of ALS.
Video: 2010 MDA Telethon ALS Research Update

MDA presents an update regarding research on ALS, featuring Dr. Timothy M. Miller from Washington University in St. Louis.